跳至主要内容
临床试验/NCT03824548
NCT03824548Unknown不适用

Real-World Analysis on the Diagnosis, Treatment Pattern and Outcomes for Patients With Gastro-Esophageal Reflux Disease (GERD) in China

Tianjin Happy Life Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 50,000 人开始时间: 2019年1月17日最近更新:
适应症

试验速览

阶段
不适用
入组人数
50,000
试验地点
1
主要终点
Proportion of GERD patients with an EE diagnosis confirmed by physician judgment vs. endoscopy

研究概览

简要总结

Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide.

GERD poses substantial burden on both patients and society. EE treatment patterns and unmet needs have been well-studied overseas, but evidence gaps still exist in China.

To fill these evidence gaps, real-world evidence for GERD and EE are needed. To understand GERD market we will analysis :Patient profile,GERD patient journey within hospital (first present, get diagnosed, receive initial and maintenance treatment),medication cost,department differentiation.

To investigate current treatment patterns of GERD / EE in China we will analysis: Current agents used and treatment duration in clinical practice treatment patterns by different reimbursement status treatment pattern by EE/NERD.

To get healing rate of EE we will analysis: Real-world efficacy of the current standard treatment (i.e. PPIs) for patient with two test results of gastroscopy.

The data required for this project are accessible in hospital electronic system; no specific data collection tools or methods are required for this project design. Only algorithms for retrieving and extracting eligible patients' records are required and will be developed by HLT based on the eligibility criteria defined in this protocol.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Medical records of GERD, NERD and/or EE diagnoses (ICD code scope will be confirmed later)from January 1st, 2015 to December 31st,
  • oGERD is typically characterized by symptoms of heartburn and acid regurgitation. A diagnosis of EE or NERD can only be confirmed upon endoscopic examination.
  • All ages, males or females
  • A primary diagnosis of GERD/NERD/EE
  • For treatment patterns, patients are also required to have received one episode of treatment during the analysis period.
  • For RW treatment efficacy, the population will be restricted to the EE treatment population who underwent at least two endoscopy examinations.

排除标准

  • No exclusion criteria will be applied for investigating diagnosis since all patients diagnosed with GERD, NERD, or EE should be captured regardless of whether they have medical conditions that affect their treatments.
  • A patient will not be eligible for investigating treatment patterns and RW treatment efficacy if he/she has any of the following exclusion criterion:
  • A post-operative diagnosis of gastrointestinal cancers
  • A diagnosis of esophageal foreign bodies or neoplasms
  • A history of gastric or esophageal surgery
  • Zollinger-Ellison syndrome
  • Primary esophageal motility disorders (ex: achalasia)
  • Esophageal strictures
  • Eosinophilic esophagitis
  • Identified as pregnant or lactating
  • Hospitalized (inpatient) patients (to be confirmed by expert.) due to GERD as primary or secondary diagnosis

结局指标

主要结局

Proportion of GERD patients with an EE diagnosis confirmed by physician judgment vs. endoscopy

时间窗: oOnly patients diagnosed between January 1st, 2015 and October 31st, 2017 will be included to allow for at least an 8-week observational period.

oAnalysis can be stratified by age group, sex, and health plan type to investigate possible differences in diagnostic practices based on these related patient characteristics.

次要结局

  • Similarly, descriptive statistics will also be presented for secondary endpoints as the analysis further examines treatment use and proxy indicators assessing real-world treatment efficacy.(Only patients diagnosed between January 1st, 2015 and October 31st, 2017 will be included to allow for at least an 8-week observational period.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验